Trademark: 87418777
Word
FIBRISTAL
Status
Dead
Status Code
605
Status Date
Wednesday, October 10, 2018
Serial Number
87418777
Mark Type
3000
Filing Date
Thursday, April 20, 2017
Published for Opposition
Tuesday, September 5, 2017
Abandoned Date
Tuesday, October 9, 2018

Trademark Owner History
Allergan Finance, LLC - Owner At Publication

Classifications
5 Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing preparations; Pharmaceuticals and medicines for the treatment and prevention of sexual dysfunction; Pharmaceuticals and medicines for the prevention and treatment of conditions affecting sensory organs; Pharmaceuticals and medicines for the prevention and treatment of conditions affecting the central nervous system; Pharmaceuticals and medicines for the prevention and treatment of conditions affecting urogenital organs; Pharmaceuticals and medicines for the prevention and treatment of conditions affecting circulatory systems; Pharmaceuticals and medicines for the treatment of cardiovascular disease and blood pressure; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceuticals and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease, dementia, AIDS-related dementia, central nervous system (CNS) disorders, neurological disorders, neurodegenerative disorders, and depression; pharmaceutical preparations, namely, neuroprotective agents; antidepressants; pharmaceuticals, namely, antipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; Pharmaceuticals used in connection with anti-aging, the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, facial aesthetic surgery, facial aesthetic reconstruction, breast aesthetics; topical antibiotics, anti-inflammatory, anti-infective, anti-glaucoma and decongestant formulations; sterile antibiotic and anti-inflammatory ointments; ocular wetting solutions, namely, eye drops, artificial tears and pharmaceutical gels for the treatment of minor ocular inflammations and allergic conditions; Pharmaceutical preparations for the treatment of neurological disorders, muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, hyperhydrosis, sports injuries, cerebral palsy, spasms, tremors and pain; dermatological formulations, namely, medicated dry skin lotions and medicated creams, acne medications and medicated skin lighteners; Pharmaceuticals and cosmeceuticals, namely, medicated skin cleansers, medicated toners, medicated moisturizers, medicated rejuvenators, medicated rehydrating creams, and medicated lotions for the face and body
Color is not claimed as a feature of the mark.
The mark consists of the word "FIBRISTAL" in lower case letters, with portions of three leaves extending generally upwards from the top of the letter "B".

Trademark Events
Oct 10, 2018
Abandonment Notice Mailed - After Publication
Oct 10, 2018
Abandonment - After Publication
Oct 9, 2018
Teas Express Abandonment Received
Oct 9, 2018
Itu Office Action Issued For Extension Request
Oct 4, 2018
Case Assigned To Intent To Use Paralegal
Sep 27, 2018
Teas Extension Received
Mar 28, 2018
Notice Of Approval Of Extension Request E-Mailed
Mar 26, 2018
Extension 1 Granted
Mar 26, 2018
Extension 1 Filed
Mar 26, 2018
Teas Extension Received
Oct 31, 2017
Noa E-Mailed - Sou Required From Applicant
Sep 5, 2017
Official Gazette Publication Confirmation E-Mailed
Sep 5, 2017
Published For Opposition
Aug 16, 2017
Notification Of Notice Of Publication E-Mailed
Jul 18, 2017
Approved For Pub - Principal Register
Jul 17, 2017
Examiner's Amendment Entered
Jul 17, 2017
Notification Of Examiners Amendment E-Mailed
Jul 17, 2017
Examiners Amendment E-Mailed
Jul 17, 2017
Examiners Amendment -Written
Jul 17, 2017
Assigned To Examiner
Apr 27, 2017
Notice Of Design Search Code E-Mailed
Apr 26, 2017
New Application Office Supplied Data Entered In Tram
Apr 24, 2017
New Application Entered In Tram

Trademark Alertz updated from USPTO on 2030-01-24